Human Growth Hormone (HGH) Treatment and Drugs Market

Human Growth Hormone (HGH) Treatment and Drugs Market Size, Market Forecast and Outlook By FMI

The human growth hormone (hgh) treatment and drugs market was valued at USD 3.9 billion in 2025. The market is set to reach USD 4.1 billion by 2026-end and grow at a CAGR of 3.5% between 2026-2036 to reach USD 5.8 billion by 2036. Recombinant Human Growth Hormone will dominate with a 68.0% share, while Subcutaneous will lead with a 74.0% share.

Key Takeaways, Market Size, and Forecast

• 2026 Market Size: USD 4.1 Bn
• 2036 Market Size: USD 5.8 Bn
• Compound Annual Growth Rate (CAGR): 3.5% from 2026 to 2036
• Absolute $ Opportunity: USD 1.7 Bn between 2026 and 2036
• Leading Product Segment: Recombinant Human Growth Hormone
• Recombinant Human Growth Hormone Share in 2026: 68.0%
• Fastest-growing Country: USA
• USA CAGR: 3.7% through 2036

Parameter	Details
Market Size in 2026 (Value)	USD 4.1 Bn
Market Forecast in 2036 (Value)	USD 5.8 Bn
CAGR (2026 to 2036)	3.5%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD Bn)
Leading Sub-Region	USA

Summary of the Human Growth Hormone (HGH) Treatment and Drugs Market

• Demand and Growth Drivers
  • Pediatric growth hormone deficiency diagnosis rates are sustaining the core patient population that drives recombinant HGH prescription volume in hospital and specialty pharmacy settings.
  • Expanding approved indications beyond classical growth hormone deficiency to include Turner syndrome, idiopathic short stature, and Prader-Willi syndrome are broadening the eligible patient population.
  • Biosimilar growth hormone entry is increasing market access and affordability in price-sensitive healthcare systems, expanding treatment uptake in markets where originator pricing limited prescription rates.
• Product and Segment View
  • Recombinant human growth hormone is expected to account for 68.0% of the product segment in 2026, reflecting the established position of somatropin products as the standard of care for growth hormone replacement.
  • Subcutaneous administration holds 74.0% of the route segment, reflecting the preference for self-administered injection devices that enable home-based treatment adherence.
  • Pediatric patients account for 72.0% of the patient age group, as growth hormone deficiency diagnosis and treatment initiation predominantly occurs during childhood growth assessment.
• Geography and Competitive Outlook
  • The USA leads growth at 3.7% CAGR through 2036, driven by CMS reimbursement pathways, specialty pharmacy distribution, and the scale of pediatric endocrinology practice.
  • South Korea at 3.6% reflects MFDS regulatory pathways for biosimilar growth hormones and healthcare system investment in pediatric specialty care.
  • Novo Nordisk, Pfizer, and Eli Lilly hold dominant positions through established somatropin brands, long-acting formulation development, and specialty pharmacy distribution networks.
• Analyst Opinion
  • Nandini Roy Choudhury, Principal Consultant at FMI says, 'Manufacturers that combine long-acting formulation convenience with competitive pricing strategies and specialty pharmacy partnerships are positioned to capture share as biosimilar competition reshapes the growth hormone treatment landscape.'
  • The HGH market is transitioning from daily injection regimens toward weekly long-acting formulations that improve patient compliance and treatment persistence, supporting premium pricing for convenience-enhanced products.
  • Biosimilar growth hormone adoption is expanding market access in European and Asian markets where originator pricing previously constrained prescription volume.
  • Demand is supported by improved diagnostic rates for growth hormone deficiency and the expansion of approved indications that broaden the eligible patient population.

Human Growth Hormone (HGH) Treatment and Drugs Market Definition

The human growth hormone treatment and drugs market includes recombinant somatropin products, biosimilar growth hormones, and combination therapies prescribed for growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, and adult growth hormone deficiency. Products span subcutaneous, intramuscular, and emerging oral delivery formats across pediatric and adult patient populations.

Human Growth Hormone (HGH) Treatment and Drugs Market Inclusions

Market scope encompasses all commercially traded HGH products categorized by product (recombinant human growth hormone, biosimilar growth hormone, combination growth hormone therapy), route of administration (subcutaneous, intramuscular, intravenous, oral), application (growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome), distribution channel (hospital pharmacy, specialty pharmacy, retail pharmacy, online pharmacy), patient age group (pediatric, adult), and therapy duration (short term therapy, medium term therapy, long term therapy). Revenue is tracked from 2026 to 2036.

Human Growth Hormone (HGH) Treatment and Drugs Market Exclusions

The scope does not include growth hormone-releasing hormone (GHRH) analogs, IGF-1 receptor agonists marketed separately, or non-prescription growth hormone supplements.

Human Growth Hormone (HGH) Treatment and Drugs Market Research Methodology

• Primary Research: FMI analysts engaged with growth hormone manufacturers, pediatric endocrinologists, specialty pharmacy operators, and health plan formulary managers across key markets.
• Desk Research: Combined prescription volume data, regulatory approval records, and clinical guideline documentation on growth hormone treatment indications and monitoring standards.
• Market Sizing and Forecasting: Bottom-up aggregation from diagnosed patient populations, treatment rates, and prescription volumes across growth hormone indications with regional healthcare access curves.
• Data Validation: Cross-checked quarterly against manufacturer sales data, specialty pharmacy dispensing records, and endocrinology practice prescription volume statistics.

Why is the Human Growth Hormone (HGH) Treatment and Drugs Growing?

• The biggest indication is pediatric growth hormone deficiency, where prescription volumes are stable, supported by improving diagnosis rates and earlier treatment initiation.
• Long-acting weekly somatropin formulations are gaining regulatory approval and clinical acceptance creating a premium priced product class that improves patient convenience and compliance.

The market for HGH treatment and drugs is expanding, as diagnostic improvements, indication expansion and formulation advances are keeping prescription growth alive. The product segment is dominated by recombinant human growth hormone with 68.0% share. The standard of care for growth hormone replacement includes established brands such as Norditropin (Novo Nordisk), Genotropin (Pfizer), and Humatrope (Eli Lilly).

The main indication is growth hormone deficiency, representing 46.0% of applications. Other approved indications: Turner syndrome, idiopathic short stature and Prader-Willi syndrome The age group is represented by pediatric patients at 72.0% which shows the predominance of diagnosis and starting of treatment in childhood, however the treatment of adult growth hormone deficiency is getting clinical recognition and prescription volume.

Pediatric growth hormone deficiency requires multi-year treatment courses and long-term therapy represents 48.0% of treatment duration. Specialty pharmacy distribution is the primary dispensing pathway for growth hormone products requiring cold chain management, patient education, and insurance prior authorization coordination (37.0% of channels).

Market Segmentation Analysis

• Somatropin products have the established standard of care position, and thus, the recombinant human growth hormone will account for 68.0% of the product segment in 2026.
• The primary clinical indication for prescribing HGH is a deficiency of growth hormone and constitutes 46.0% of demand for application.
• Most of the age group (72.0%) are pediatric patients because growth hormone treatment is commonly started in the course of childhood growth assessment and monitoring.

The HGH treatment and drugs market is segmented by product, route of administration, application, distribution channel, patient age group, and therapy duration. Product types include recombinant HGH, biosimilar, and combination therapies across subcutaneous and other administration routes.

Insights into the Recombinant Human Growth Hormone Segment

Recombinant HGH accounts for 68.0% of the product segment in 2026. Somatropin products produced through recombinant DNA technology provide bioidentical growth hormone replacement for deficient patients. Daily subcutaneous injection has been the standard administration, though weekly long-acting formulations are gaining market share.

Growth reflects the stability of the diagnosed patient population and the premium pricing of long-acting formulations that improve patient convenience. Manufacturers differentiate through injection device design, pen convenience features, and patient support programs that improve treatment adherence.

Insights into the Biosimilar Growth Hormone Segment

As patents on the originator products expire, biosimilar growth hormones are gaining market share as lower cost options. European markets are setting the pace for biosimilar uptake, with Sandoz, Teva and other manufacturers providing somatropin biosimilars that expand access in price-sensitive healthcare systems.

“The market is getting bigger with biosimilar use as treatment is now reaching patient populations and healthcare systems that had lower prescription rates due to originator pricing. Payer formulary positioning and automatic substitution policies across markets impact biosimilar uptake rates.

Human Growth Hormone (HGH) Treatment and Drugs Market Drivers, Restraints, and Opportunities

• Diagnosis rates for pediatric growth hormone deficiency are maintained at the base patient population level, with screening and referral pathways improving and driving an increased percentage of diagnosed and treated patients.
• Pricing pressure on originator products from biosimilar competition and patent expiry shifts market share but increases overall treatment access.
• Long-acting weekly formulations are a product lifecycle extension opportunity that enables premium pricing and differentiation from daily injection biosimilar competition.

The market for HGH is affected by patient demographics, regulatory pathways, and the competitive dynamics between originator and biosimilar products. Growth is driven by expanding indications, improving diagnostics and innovating formulations.

Diagnostic Improvement and Treatment Rates

Improved pediatric screening programs and access to endocrinologists are improving the percentage of growth hormone deficient children who are diagnosed and treated. Earlier diagnosis and treatment initiation improves the clinical outcomes and generate longer treatment duration per patient which supports the market revenue growth.

Biosimilar Competition and Market Expansion

Biosimilar somatropin products are emerging in the major markets as originator patents expire. Biosimilars enable treatment in cost-sensitive healthcare systems, stimulating pricing competition and expanding overall market access. The speed of biosimilar adoption is driven by payer formulary management and physician prescribing patterns.

Long-Acting Formulation Innovation

Long-acting somatropin products (e.g. Novo Nordisk’s Sogroya and other pipeline candidates) reduce injection burden from daily to weekly administration. “It’s a convenience improvement that helps with adherence and deserves a premium price to differentiate from the competition in the daily injection space.

Analysis of Human Growth Hormone (HGH) Treatment and Drugs Market By Key Countries

Country	CAGR
USA	3.7%
UK	3.3%
EU	3.4%
Japan	3.2%
South Korea	3.6%

• The USA leads at 3.7% CAGR, driven by CMS reimbursement for growth hormone therapy, specialty pharmacy infrastructure, and the scale of pediatric endocrinology practice.
• South Korea at 3.6% reflects MFDS biosimilar pathways and healthcare investment in pediatric specialty care.
• The EU at 3.4% generates demand through biosimilar adoption and expanded indication coverage across member state healthcare systems.

The global HGH treatment and drugs market is projected to expand at a CAGR of 3.5% from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for Human Growth Hormone (HGH) Treatment and Drugs Market in the United States

The USA leads at 3.7% through 2036. CMS reimbursement pathways for growth hormone therapy and FDA approval of long-acting somatropin formulations sustain premium pricing and prescription volume. Specialty pharmacy networks manage prior authorization, cold chain, and patient adherence support for HGH products.

• CMS reimbursement sustains coverage for pediatric and adult growth hormone deficiency treatment indications.
• FDA approval of long-acting weekly somatropin creates a premium-priced product category improving patient convenience.
• Specialty pharmacy distribution manages the complex dispensing requirements of growth hormone products.

Future Outlook for Human Growth Hormone (HGH) Treatment and Drugs Market in South Korea

South Korea grows at 3.6% through 2036. MFDS regulatory pathways for biosimilar growth hormone approval create market access for lower-cost alternatives. Government healthcare investment in pediatric specialty services and smart manufacturing capabilities in biopharmaceutical production support domestic growth hormone manufacturing.

• The MFDS biosimilar pathways enable a lower-cost market entry of biosimilar growth hormone alternatives.
• Government investment in healthcare for pediatric specialty care improves diagnosis and treatment rates.
• Smart biopharmaceutical manufacturing capabilities support domestic growth hormone production.

Opportunity Analysis of Human Growth Hormone (HGH) Treatment and Drugs Market in the European Union

EU at 3.4% growth through 2036. Regulatory frameworks and reimbursement policies of member states for EMA biosimilar somatropin influence market access and pricing. Product delivery system specification is impacted by ecodesign considerations for pharmaceutical packaging and regulation of injection devices adjacent to EU MDR.

• EMA biosimilar pathways provide cost-effective access to growth hormone in EU member state healthcare systems.
• Formulary inclusion and prescription volume of HGH products are determined by the reimbursement policies of member states.
• EU regulations on pharmaceutical packaging impact the design of injection devices and the specification of cold chain packaging.

In-depth Analysis of Human Growth Hormone (HGH) Treatment and Drugs Market in Japan

Japan grows at 3.2% through 2036. PMDA regulatory pathways and long product qualification timeline are quality barriers to growth hormone products. In endocrinology practice, the demographics of an aging population increase the awareness of adult growth hormone deficiency and the initiation of treatment.

• PMDA regulatory pathways maintain product quality standards that favor established growth hormone manufacturers.
• Adult growth hormone deficiency diagnosis is gaining clinical recognition in Japanese endocrinology practice.
• Long qualification timelines create stable market positions for approved growth hormone products.

Sales Analysis of Human Growth Hormone (HGH) Treatment and Drugs Market in the United Kingdom

UK growth to accelerate to 3.3% by 2036. The impact of NHS formulary management and NICE technology appraisal on growth hormone products: patterns of prescription. Post-Brexit MHRA regulatory pathways create separate growth hormone product approval processes for products marketed in the UK.

• Hospital trusts manage the access and volume of growth hormone prescriptions through NHS formulary management.
• Impact of NICE technology appraisals on cost-effectiveness of originator versus biosimilar growth hormones.
• Post-Brexit MHRA pathways define UK-specific regulatory requirements for the marketing of growth hormone products.

Competitive Landscape and Strategic Positioning

• Novo Nordisk has leadership with Norditropin and its Sogroya long-acting weekly formulation, integrating established brand recognition with formulation innovation.
• Pfizer and Eli Lilly compete with Genotropin and Humatrope, respectively, through their established endocrinologist relationships and distribution through specialty pharmacies.
• Biosimilar makers like Sandoz and Teva are picking up market share with lower-cost somatropin alternatives in Europe and Asia.

Novo Nordisk is the market leader with Norditropin, the best-selling daily somatropin, and Sogroya, a long-acting weekly growth hormone. The company uses its diabetes care distribution infrastructure and patient support programs to serve growth hormone patients, both pediatric and adult.

Genotropin is in competition with its established pen delivery system. Humatrope (Eli Lilly) is indicated for pediatric and adult use. Merck KGaA sells Saizen and Ferring Pharmaceuticals sells Zomacton for treatment of growth hormone deficiency.

In price-sensitive healthcare systems, biosimilar competitors such as Sandoz (Omnitrope), Teva and others are increasing market access. Long-acting formulation development (TransCon hGH) from Ascendis Pharma is a pipeline category that might further change competitive dynamics.

Key Companies in the Human Growth Hormone (HGH) Treatment and Drugs Market

Key global companies leading the human growth hormone (hgh) treatment and drugs market include:

• Novo Nordisk (Denmark), Pfizer (USA) and Eli Lilly (USA) are global leaders thanks to established somatropin brands, development of long-acting formulations and use of specialty pharmacy distribution networks.
• The regional distribution and endocrinology specialist relationships are driving growth hormone indications for Merck KGaA (Germany) and Ferring Pharmaceuticals (Switzerland).
• Sandoz (Switzerland), Teva (Israel) and emerging biosimilar manufacturers are gaining share with cheaper versions of somatropin that increase market access.

Competitive Benchmarking: Human Growth Hormone (HGH) Treatment and Drugs Market

Company	Brand Portfolio	Long-Acting Pipeline	Distribution Network	Geographic Reach
Novo Nordisk	Strong	Approved	Extensive	Global
Pfizer	Strong	In Development	Extensive	Global
Eli Lilly	Strong	In Development	Extensive	Global
Merck KGaA	Medium	Low	Strong	Europe, Global
Ferring Pharma	Medium	Low	Moderate	Europe, Asia
Sandoz Group AG	Biosimilar	N/A	Strong	Global
Ascendis Pharma	Pipeline	Advanced	Building	USA, Europe

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Human Growth Hormone (HGH) Treatment and Drugs Market

• Novo Nordisk, Market Expansion, Sogroya Growth Hormone Therapy (2025) - Novo Nordisk continued expanding the commercial availability and adoption of Sogroya (somapacitan), its once-weekly growth hormone therapy, across key international markets for pediatric and adult growth hormone deficiency.
• Ascendis Pharma, Regulatory Approval, SKYTROFA® for Adult Growth Hormone Deficiency (2025) - Ascendis Pharma received FDA approval for SKYTROFA® (lonapegsomatropin-tcgd) for adults with growth hormone deficiency, strengthening the long-acting growth hormone treatment segment.

Key Players in the Human Growth Hormone (HGH) Treatment and Drugs Market

Major Global Players

• Novo Nordisk A/S
• Pfizer Inc.
• Eli Lilly and Company
• Merck KGaA
• Ferring Pharmaceuticals

Emerging Players/Startups

• Sandoz Group AG
• Teva Pharmaceutical Industries
• Ascendis Pharma
• OPKO Health
• AnkeBio Co. Ltd.
• GeneScience Pharmaceuticals

Report Scope and Coverage

Parameter	Details
Market size by 2036	USD 5.8 Bn
Growth rate	3.5% CAGR (2026 to 2036)
Forecast period	2026 to 2036
Base year value (2025)	USD 4.0 Bn
Key Segment Covered	Product, Route of Administration, Application, Distribution Channel, Patient Age Group, Therapy Duration
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, South Korea, UK, Japan, EU, 30 plus countries
Key companies profiled	Novo Nordisk, Pfizer, Eli Lilly, Merck KGaA, Ferring Pharmaceuticals, Sandoz, Ascendis Pharma
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Product:

• Recombinant Human Growth Hormone
  • Daily Growth Hormone Therapy
    • Short Acting Somatropin
    • Conventional Daily Injection Therapy
  • Long Acting Growth Hormone Therapy
    • Weekly Growth Hormone Therapy
    • Extended Release Somatropin
• Biosimilar Growth Hormone
  • Pediatric Biosimilar Therapy
    • Cost Effective Pediatric Treatment
    • Hospital Based Biosimilar Therapy
  • Adult Biosimilar Therapy
    • Adult Hormone Replacement Therapy
    • Long Duration Biosimilar Treatment
• Combination Growth Hormone Therapy
  • Growth Hormone with Hormonal Therapy
    • Endocrine Combination Therapy
    • Puberty Management Therapy
  • Growth Hormone with Nutritional Support
    • Metabolic Support Therapy
    • Pediatric Nutritional Therapy

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Route of Administration:

• Subcutaneous
  • Prefilled Injection Pens
    • Disposable Injection Pens
    • Reusable Injection Pens
  • Auto Injector Systems
    • Needle Assisted Injectors
    • Needle Free Injectors
• Intramuscular
  • Clinic Based Intramuscular Therapy
    • Hospital Administered Therapy
    • Specialist Endocrinology Administration
  • Long Acting Intramuscular Therapy
    • Extended Release Intramuscular Therapy
    • Controlled Dose Administration
• Intravenous
  • Hospital Intravenous Administration
    • Acute Hormonal Therapy
    • Critical Care Hormonal Therapy
  • Specialized Intravenous Delivery
    • Monitored Infusion Therapy
    • Clinical Research Therapy
• Oral
  • Oral Growth Hormone Formulations
    • Peptide Based Oral Therapy
    • Enhanced Absorption Formulations
  • Novel Oral Delivery Systems
    • Nanotechnology Based Delivery
    • Delayed Release Oral Therapy

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Application:

• Growth Hormone Deficiency
  • Pediatric Growth Hormone Deficiency
    • Congenital Growth Hormone Deficiency
    • Acquired Growth Hormone Deficiency
  • Adult Growth Hormone Deficiency
    • Pituitary Disorder Related Deficiency
    • Age Related Hormone Deficiency
• Turner Syndrome
  • Pediatric Turner Syndrome Therapy
    • Growth Promotion Therapy
    • Long Term Hormonal Management
  • Adolescent Turner Syndrome Therapy
    • Pubertal Support Therapy
    • Metabolic Regulation Therapy
• Idiopathic Short Stature
  • Childhood Idiopathic Short Stature
    • Early Intervention Therapy
    • Growth Acceleration Therapy
  • Adolescent Idiopathic Short Stature
    • Late Stage Growth Therapy
    • Height Optimization Therapy
• Prader Willi Syndrome
  • Pediatric Prader Willi Syndrome Therapy
    • Metabolic Regulation Therapy
    • Body Composition Therapy
  • Adolescent and Adult Therapy
    • Weight Management Support
    • Muscle Development Therapy
• Other Applications
  • Chronic Kidney Disease Related Growth Failure
    • Pediatric Renal Growth Therapy
    • Long Term Renal Hormonal Therapy
  • Small For Gestational Age Treatment
    • Catch Up Growth Therapy
    • Infant Growth Management
  • HIV Related Wasting Syndrome
    • Muscle Mass Restoration Therapy
    • Metabolic Support Therapy

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Distribution Channel:

• Hospital Pharmacy
  • Public Hospital Pharmacy
    • Government Endocrine Supply
    • Institutional Hormone Dispensing
  • Private Hospital Pharmacy
    • Specialty Hormonal Dispensing
    • Advanced Biologic Pharmacy
• Specialty Pharmacy
  • Endocrinology Specialty Pharmacy
    • Pediatric Hormone Therapy Dispensing
    • Rare Disorder Pharmacy Services
  • Biologic Specialty Pharmacy
    • Cold Chain Hormonal Distribution
    • Patient Adherence Support
• Retail Pharmacy
  • Chain Retail Pharmacy
    • Urban Retail Hormone Supply
    • Prescription Refill Services
  • Independent Retail Pharmacy
    • Community Endocrine Dispensing
    • Regional Hormone Distribution
• Online Pharmacy
  • Digital Prescription Platforms
    • Direct To Patient Delivery
    • Subscription Hormonal Therapy
  • E Commerce Pharmacy Platforms
    • Cold Chain Home Delivery
    • Remote Therapy Management

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Patient Age Group:

• Pediatric
  • Infant Therapy
    • Neonatal Hormonal Support
    • Early Childhood Growth Therapy
  • Child and Adolescent Therapy
    • Pubertal Growth Management
    • Long Term Growth Therapy
• Adult
  • Adult Hormone Replacement Therapy
    • Pituitary Deficiency Therapy
    • Metabolic Hormone Therapy
  • Geriatric Hormone Therapy
    • Age Related Hormonal Support
    • Muscle Maintenance Therapy

Human Growth Hormone (HGH) Treatment and Drugs Market Segmented by Therapy Duration:

• Short Term Therapy
  • Up To 1 Year Treatment
    • Initial Hormonal Correction
    • Early Growth Therapy
• Medium Term Therapy
  • 1 Year To 3 Year Treatment
    • Pediatric Growth Maintenance
    • Developmental Hormonal Therapy
• Long Term Therapy
  • Above 3 Year Treatment
    • Chronic Endocrine Therapy
    • Continuous Growth Support

Human Growth Hormone (HGH) Treatment and Drugs Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Growth Hormone Treatment Guidelines and Pediatric Endocrinology Standards. WHO.
• 2. International Organization for Standardization. (2025). ISO Standards for Biopharmaceutical Product Quality and Injection Device Safety. ISO.
• 3. Novo Nordisk A/S. (2025). Annual Report: Biopharmaceuticals Division Performance and Growth Hormone Portfolio Review. Novo Nordisk.
• 4. USA Food and Drug Administration. (2025). FDA Growth Hormone Product Approval and Biosimilar Regulatory Pathways. FDA.
• 5. European Medicines Agency. (2025). EMA Biosimilar Somatropin Approval Guidelines and Post-Market Surveillance. EMA.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the market and how much money it will make from 2026 to 2036.
• Dividing up by product, route of administration, application, distribution channel, patient age group, and therapy duration.
• Insights about more than 30 markets in the region.
• Analysis of HGH product categories including recombinant, biosimilar, and long-acting formulations.
• Assessment of the competitive landscape.
• Finding investment opportunities in pediatric, adult, and specialty growth hormone treatment applications.
• Keeping track of the supply chain.
• Delivery of data in PDF and Excel formats.